Biopharma IPOs Start To Gear Up For 2013 After A Lull
Executive Summary
Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.
You may also be interested in...
J.P. Morgan Notebook: Tuesday January 14
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the second day of the 2014 J.P. Morgan health care conference, including news from ZS Pharma, Aisling Capital, Astellas, and Moderna.
With A Drug On The Fast Track, Chimerix Aims To Go Public
Once wary of the IPO market, the antiviral drug developer looks to public investors as it prepares to fund a Phase III trial for a well-regarded but unpartnered cytomegalovirus drug.
Financings Of The Fortnight Ponders Sequester Fallout Potential For Biotech
Plus news on recent financings by Tesaro, Ablynx, Spring Bank Pharmaceuticals and Daiichi Sankyo.